TY - JOUR
T1 - The translational imperative
T2 - Making cell therapy simple and effective
AU - Prestwich, Glenn D.
AU - Erickson, Isaac E.
AU - Zarembinski, Thomas I.
AU - West, Michael
AU - Tew, William P.
N1 - Funding Information:
We thank the NIH for the original basic research grant that allowed development of the sECMs (R01 DC 04336), applied research awards (SBIRs to Glycosan), the University of Utah, and the State of Utah Centers of Excellence Program for financial support. We also thank collaborators and customers for sharing their results and suggestions, and for propelling us toward addressing unmet market needs for cell therapy.
PY - 2012/12
Y1 - 2012/12
N2 - The current practice of cell therapy, in which multipotent or terminally differentiated cells are injected into tissues or intravenously, is inefficient. Few therapeutic cells are retained at the site of administration and engraftment is low. An injectable and biologically appropriate vehicle for delivery, retention, growth and differentiation of therapeutic cells is needed to improve the efficacy of cell therapy. We focus on a hyaluronan-based semi-synthetic extracellular matrix (sECM), HyStem®, which is a manufacturable, approvable and affordable clinical product. The composition of this sECM can be customized for use with mesenchymal stem cells as well as cells derived from embryonic or induced pluripotent sources. In addition, it can support therapeutic uses of progenitor and mature cell populations obtained from skin, fat, liver, heart, muscle, bone, cartilage, nerves and other tissues. This overview presents four pre-clinical uses of HyStem® for cell therapy to repair injured vocal folds, improve post-myocardial infarct heart function, regenerate damaged liver tissue and restore brain function following ischemic stroke. Finally, we address the real-world limitations - manufacture, regulation, market acceptance and financing - surrounding cell therapy and the development of clinical combination products.
AB - The current practice of cell therapy, in which multipotent or terminally differentiated cells are injected into tissues or intravenously, is inefficient. Few therapeutic cells are retained at the site of administration and engraftment is low. An injectable and biologically appropriate vehicle for delivery, retention, growth and differentiation of therapeutic cells is needed to improve the efficacy of cell therapy. We focus on a hyaluronan-based semi-synthetic extracellular matrix (sECM), HyStem®, which is a manufacturable, approvable and affordable clinical product. The composition of this sECM can be customized for use with mesenchymal stem cells as well as cells derived from embryonic or induced pluripotent sources. In addition, it can support therapeutic uses of progenitor and mature cell populations obtained from skin, fat, liver, heart, muscle, bone, cartilage, nerves and other tissues. This overview presents four pre-clinical uses of HyStem® for cell therapy to repair injured vocal folds, improve post-myocardial infarct heart function, regenerate damaged liver tissue and restore brain function following ischemic stroke. Finally, we address the real-world limitations - manufacture, regulation, market acceptance and financing - surrounding cell therapy and the development of clinical combination products.
KW - Cell engraftment
KW - Cell therapy
KW - ECM
KW - HyStem®
KW - Hyaluronic acid
UR - http://www.scopus.com/inward/record.url?scp=84868203733&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868203733&partnerID=8YFLogxK
U2 - 10.1016/j.actbio.2012.06.043
DO - 10.1016/j.actbio.2012.06.043
M3 - Article
C2 - 22776825
AN - SCOPUS:84868203733
SN - 1742-7061
VL - 8
SP - 4200
EP - 4207
JO - Acta Biomaterialia
JF - Acta Biomaterialia
IS - 12
ER -